Asymptomatic hyperuricemia: is it time to intervene?

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Hyperuricemia, or high uric acid levels, is increasingly linked to cardiovascular disease (CVD) and chronic kidney disease (CKD).
• The decision to treat uncomplicated hyperuricemia without gout or kidney stones remains debated.
• Existing evidence suggests a potential causative relationship between hyperuricemia and these conditions.

Purpose of the Study:

• To evaluate the clinical judgment involved in treating hyperuricemia.
• To identify patient subgroups who may benefit from urate-lowering therapy.
• To discuss the evolving understanding of hyperuricemia's role in CVD and CKD.

Main Methods:

• Review of current clinical practices and evidence regarding hyperuricemia treatment.
• Analysis of the association between hyperuricemia and comorbidities like coronary artery disease, CKD, and hypertension.
• Synthesis of existing research on the benefits of urate-lowering therapy.

Main Results:

• Universal agreement on treating asymptomatic hyperuricemia is lacking.
• Patients with persistent hyperuricemia and conditions like coronary artery disease, CKD, or early hypertension may benefit from urate-lowering therapy.
• Evidence supporting a causative link between hyperuricemia and CVD/CKD is growing.

Conclusions:

• Pharmacotherapy for asymptomatic hyperuricemia is not universally recommended.
• Further studies are required to determine specific patient populations and uric acid thresholds for beneficial urate-lowering treatment.
• Clinical judgment remains crucial in managing hyperuricemia.